Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts rate Roivant Sciences “Moderate Buy”: Nine of 12 brokerages recommend buying the stock, with an average 12-month price target of $35.14. Recent targets range as high as $46, including upgrades from Citigroup and Guggenheim.
• Insiders have been selling shares: Company insiders sold 2.06 million shares worth approximately $69.6 million during the last quarter, including a 200,000-share sale by CEO Eric Venker under a Rule 10b5-1 plan.
• ROIV opened at $36.24, near its 52-week high of $37.19, and has a market capitalization of about $26.2 billion. Institutional investors own 64.76% of the company.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $35.1364.

A number of equities analysts have recently weighed in on the company. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research note on Thursday, May 21st. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Citigroup upped their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th. Finally, Guggenheim lifted their price objective on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 7th.

Insider Buying and Selling

In related news, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares of the company's stock, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the sale, the director owned 16,474 shares in the company, valued at approximately $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,055,913 shares of company stock worth $69,639,633. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in the company. Fifth Third Bancorp boosted its stake in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock valued at $130,000 after buying an additional 376 shares during the last quarter. Bessemer Group Inc. increased its stake in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after acquiring an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after acquiring an additional 445 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Roivant Sciences by 13.9% during the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock worth $141,000 after acquiring an additional 487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock valued at $1,891,000 after acquiring an additional 500 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $36.24 on Tuesday. Roivant Sciences has a 52-week low of $11.54 and a 52-week high of $37.19. The firm has a market capitalization of $26.18 billion, a PE ratio of -68.38 and a beta of 1.12. The stock has a fifty day simple moving average of $34.00 and a two-hundred day simple moving average of $30.06.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source